Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Victorian Clinical Genetics Services, |
RCV001089999 | SCV001245040 | likely pathogenic | 3-hydroxy-3-methylglutaryl-CoA synthase deficiency | 2019-01-07 | criteria provided, single submitter | clinical testing | A heterozygous missense variant, NM_005518.3(HMGCS2):c.512C>T, has been identified in exon 2 of 10 of the HMGCS2 gene. The variant is predicted to result in a minor amino acid change from alanine to valine at position 171 of the protein (NP_005509.1(HMGCS2):p.(Ala171Val)). The alanine residue at this position has moderate conservation (100 vertebrates, UCSC), and is located within the HMG_CoA synthase N terminal functional domain. In silico predictions of pathogenicity for this variant are conflicting (Polyphen, SIFT, CADD, Mutation Taster). The variant is absent in the gnomAD population database, and has not been previously reported in clinical cases. Analysis of parental samples indicated this variant was paternally inherited. Following multidisciplinary clinical review of this case, this variant was determined to be highly concordant with the phenotypic presentation of the patient. Based on the information available at the time of curation, this variant has been classified as LIKELY PATHOGENIC. The presence of these two variants in trans confirms a compound heterozygous mode of inheritance which is consistent with HMG-CoA synthase-2 deficiency. |